Lys9
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys9  -  H3 (human)

Site Information
rtkQtArkstGGkAP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 463820
Available spectra:  3 CST

In vivo Characterization
Methods used to characterize site in vivo:
[14C] acetate labeling ( 64 , 78 ) , flow cytometry ( 4 , 5 , 16 , 18 , 43 ) , immunoassay ( 72 , 80 , 145 , 146 , 154 , 174 , 241 ) , immunoprecipitation ( 3 , 5 , 6 , 7 , 8 , 9 , 10 , 12 , 14 , 15 , 17 , 18 , 24 , 28 , 38 , 44 , 55 , 59 , 60 , 62 , 68 , 69 , 73 , 74 , 76 , 103 , 129 , 147 , 148 , 150 , 153 , 155 , 163 , 170 , 175 , 177 , 179 , 181 , 182 , 200 , 201 , 225 , 250 , 251 , 256 , 260 , 263 , 264 , 265 , 266 , 289 , 383 , 403 , 404 , 405 ) , mass spectrometry ( 32 , 36 , 41 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 56 , 57 , 58 , 65 , 66 , 67 , 79 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 141 , 142 , 143 , 150 , 151 , 152 , 157 , 158 , 159 , 160 , 161 , 164 , 165 , 166 , 167 , 172 , 173 , 176 , 177 , 185 , 186 , 187 , 188 , 189 , 190 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 198 , 203 , 204 , 205 , 206 , 207 , 208 , 211 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 , 220 , 221 , 222 , 223 , 224 , 226 , 227 , 228 , 229 , 230 , 231 , 232 , 233 , 234 , 235 , 236 , 237 , 238 , 239 , 240 , 242 , 243 , 244 , 245 , 246 , 247 , 248 , 252 , 253 , 257 , 258 , 259 , 261 , 262 , 268 , 269 , 270 , 271 , 272 , 273 , 274 , 275 , 276 , 277 , 279 , 280 , 282 , 283 , 284 , 285 , 286 , 287 , 288 , 291 , 292 , 293 , 294 , 295 , 296 , 297 , 298 , 299 , 300 , 301 , 302 , 303 , 304 , 305 , 306 , 307 , 308 , 309 , 310 , 311 , 312 , 313 , 314 , 315 , 316 , 317 , 318 , 319 , 320 , 321 , 322 , 323 , 324 , 325 , 326 , 327 , 328 , 329 , 330 , 332 , 333 , 334 , 335 , 336 , 337 , 338 , 339 , 340 , 341 , 342 , 343 , 344 , 345 , 346 , 347 , 348 , 349 , 350 , 351 , 352 , 353 , 354 , 355 , 356 , 357 , 358 , 359 , 360 , 361 , 362 , 363 , 364 , 365 , 366 , 367 , 368 , 369 , 370 , 371 , 372 , 373 , 374 , 375 , 376 , 377 , 378 , 379 , 380 , 381 , 384 , 385 , 386 , 387 , 388 , 389 , 390 , 391 , 392 , 394 , 395 , 396 , 397 , 399 , 400 , 401 , 402 ) , mass spectrometry (in vitro) ( 64 , 78 , 184 , 209 ) , modification-specific antibody ( 1 , 2 , 3 , 5 , 11 , 12 , 13 , 14 , 16 , 17 , 21 , 24 , 26 , 28 , 29 , 32 , 33 , 34 , 35 , 37 , 38 , 39 , 40 , 44 , 55 , 59 , 61 , 62 , 63 , 68 , 69 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 80 , 103 , 129 , 130 , 140 , 144 , 145 , 146 , 147 , 148 , 149 , 153 , 154 , 155 , 156 , 168 , 169 , 170 , 171 , 174 , 175 , 178 , 179 , 180 , 181 , 182 , 183 , 200 , 201 , 202 , 225 , 241 , 250 , 254 , 256 , 263 , 265 , 266 , 278 , 289 , 290 , 317 , 381 , 382 , 383 , 403 , 404 , 405 , 406 , 407 ) , multiple reaction monitoring (MRM) ( 128 ) , mutation of modification site ( 7 , 9 , 18 , 70 , 130 , 144 , 177 , 251 , 407 ) , phospho-antibody ( 5 , 33 , 44 , 162 , 210 , 251 , 264 , 265 , 398 , 405 ) , western blotting ( 1 , 2 , 3 , 5 , 7 , 8 , 9 , 10 , 11 , 12 , 14 , 15 , 16 , 17 , 18 , 21 , 24 , 26 , 29 , 32 , 33 , 34 , 35 , 38 , 39 , 40 , 60 , 61 , 62 , 63 , 69 , 70 , 71 , 72 , 76 , 77 , 80 , 130 , 140 , 144 , 146 , 149 , 150 , 156 , 162 , 168 , 169 , 171 , 174 , 177 , 178 , 180 , 183 , 201 , 202 , 210 , 251 , 260 , 263 , 265 , 278 , 290 , 317 , 398 , 403 , 405 , 407 )
Disease tissue studied:
bone cancer ( 180 , 263 ) , osteosarcoma ( 263 ) , brain cancer ( 250 , 265 ) , glioblastoma ( 265 ) , glioma ( 265 ) , medulloblastoma ( 250 ) , breast cancer ( 7 , 15 , 21 , 36 , 43 , 150 , 156 , 225 , 265 , 383 ) , breast adenocarcinoma ( 21 ) , breast cancer, triple negative ( 21 , 43 ) , cervical cancer ( 32 , 200 , 289 , 389 , 404 ) , cervical adenocarcinoma ( 200 , 289 , 389 , 404 ) , cervical squamous cell carcinoma ( 32 ) , colorectal cancer ( 1 , 32 , 33 , 60 , 75 , 141 , 142 , 143 , 149 , 151 , 155 , 178 , 186 , 187 , 191 , 192 , 195 , 198 , 214 , 216 , 218 , 220 , 222 , 224 , 230 , 232 , 254 , 265 , 405 , 406 ) , colorectal carcinoma ( 1 , 32 , 33 , 60 , 75 , 141 , 142 , 143 , 149 , 151 , 155 , 178 , 254 , 265 , 405 , 406 ) , colorectal cancer, surrounding tissue ( 213 , 215 , 217 , 221 , 223 , 228 , 229 , 231 , 233 ) , gastric cancer ( 11 , 65 , 170 ) , gastric carcinoma ( 11 , 170 ) , HNSCC ( 38 ) , leukemia ( 13 , 14 , 16 , 59 , 60 , 103 , 127 , 128 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 153 , 178 , 250 , 289 ) , acute lymphocytic leukemia ( 127 ) , acute myelogenous leukemia ( 59 , 60 , 153 , 250 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 60 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 250 ) , chronic myelogenous leukemia ( 13 , 14 , 16 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 289 ) , T cell leukemia ( 60 , 103 , 289 ) , liver cancer ( 15 , 158 , 159 , 161 , 174 , 254 , 398 , 399 , 400 , 401 , 403 ) , hepatocellular carcinoma ( 399 , 400 , 401 ) , liver cancer, surrounding tissue ( 157 , 160 ) , lung cancer ( 15 , 34 , 41 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 148 , 265 , 314 , 373 ) , non-small cell lung cancer ( 15 , 34 , 46 , 47 , 48 , 51 , 52 , 53 , 57 , 58 , 66 , 67 , 148 , 265 , 314 , 373 ) , non-small cell lung adenocarcinoma ( 15 , 34 , 41 , 45 , 46 , 47 , 48 , 51 , 52 , 58 , 148 , 314 , 373 ) , non-small cell large cell lung carcinoma ( 46 , 52 , 265 ) , non-small cell squamous cell lung carcinoma ( 45 , 67 ) , small-cell lung cancer ( 49 , 50 , 381 ) , lymphoma ( 12 , 39 , 60 , 128 , 153 , 210 ) , anaplastic large cell lymphoma ( 60 ) , B cell lymphoma ( 12 , 39 ) , non-Hodgkin's lymphoma ( 12 , 39 ) , follicular lymphoma ( 39 ) , mantle cell lymphoma ( 12 ) , ovarian cancer ( 29 , 43 ) , ovarian epithelial carcinoma ( 43 ) , pancreatic cancer ( 37 ) , pancreatic carcinoma ( 37 ) , prostate cancer ( 24 , 26 , 60 , 76 , 169 , 264 ) , fibrosarcoma of soft tissue ( 43 ) , cancer, squamous cell carcinoma ( 32 ) , thymic carcinoma ( 109 ) , ventricular tachycardia ( 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 104 , 105 , 106 , 107 , 108 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 ) , SLE ( 3 )
Relevant cell line - cell type - tissue:
'muscle, skeletal' ( 168 , 251 ) , 'neuron, cerebellar granule' ( 80 ) , 'neuron, cortical'-brain ( 80 ) , 'stem, embryonic' ( 36 , 74 , 260 , 278 ) , 'stem, hematopoietic' ( 35 ) , 'stem, induced pluripotent' ( 28 ) , 'stem, trophoblast' ( 36 ) , 22Rv1 (prostate cell) ( 26 ) , 293 (epithelial) ( 9 , 10 , 79 , 174 , 317 , 392 ) , 3T3 (fibroblast) ( 177 , 317 ) , 4T1 (breast cell) ( 15 ) , A20 (B lymphocyte) ( 12 ) , A2780 (ovarian) ( 43 ) , A549 (pulmonary) ( 15 , 34 , 41 , 51 , 148 , 240 , 242 ) , AGS (gastric) ( 11 ) , ARH-77 (B lymphocyte) ( 178 ) , B lymphocyte-blood ( 3 ) , BGC823 (gastric) ( 170 ) , Bl21 ( 199 ) , blood ( 4 ) , brain ( 256 ) , breast ( 7 ) , BxPC-3 (pancreatic) ( 37 ) , C2C12 (myoblast) ( 18 ) , C4-2 (prostate cell) ( 24 ) , Caco-2 (intestinal) ( 33 , 155 ) , Cal-12T (pulmonary) ( 47 ) , Calu-1 (squamous) ( 2 ) , Calu-3 (pulmonary) ( 53 ) , cardiac-heart ( 82 , 83 , 85 , 86 , 87 , 88 , 89 , 90 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 102 , 104 , 106 , 107 , 110 , 111 , 112 , 113 , 114 , 115 , 117 , 118 , 119 , 120 , 122 , 123 , 124 , 125 , 126 ) , CCD-1079Sk (fibroblast) ( 74 ) , colon ( 185 , 186 , 187 , 188 , 189 , 190 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 198 , 213 , 214 , 215 , 216 , 217 , 218 , 220 , 221 , 222 , 223 , 224 , 228 , 229 , 230 , 231 , 232 , 233 ) , COS (fibroblast) ( 251 ) , CV ( 264 ) , D283 ( 250 ) , Daoy ( 250 ) , dendritic cell ( 17 ) , DMS153 (pulmonary) ( 48 ) , DMS53 (pulmonary) ( 50 ) , DMS79 (pulmonary) ( 49 ) , DU 145 (prostate cell) ( 169 ) , E.coli (bacterial) ( 177 ) , endothelial-retina ( 55 ) , esophageal ( 154 ) , FaDu (squamous) ( 32 ) , GH4C1 (pituitary cell) ( 179 ) , GM06990 (lymphoblast) ( 289 ) , H9c2 (myoblast) ( 9 ) , HCC15 (pulmonary) ( 45 ) , HCC44 (pulmonary) ( 47 ) , HCC78 (pulmonary) ( 46 , 371 , 372 , 374 ) , HCC827 (pulmonary) ( 53 , 314 , 373 ) , HCT116 (intestinal) ( 1 , 32 , 60 , 75 , 141 , 142 , 143 , 151 , 211 , 212 , 252 , 253 , 261 , 262 , 311 , 312 , 361 , 362 , 363 , 375 , 376 , 405 , 406 ) , heart ( 73 , 256 , 290 ) , HEK293T (epithelial) ( 8 , 18 , 38 , 70 , 144 , 177 , 382 ) , HEL (erythroid) ( 60 ) , HeLa (cervical) ( 44 , 54 , 62 , 77 , 146 , 174 , 180 , 202 , 317 , 402 ) , HeLa S3 (cervical) ( 200 , 289 , 377 , 389 , 404 ) , hepatocyte ( 74 ) , HepG2 (hepatic) ( 15 , 174 , 254 , 394 , 395 , 398 , 399 , 400 , 401 , 403 ) , HESCs (endometrial) ( 178 ) , HFL1 ( 289 ) , HL60 (myeloid) ( 128 ) , HMEC (endothelial) ( 175 ) , HN12 (squamous) ( 38 ) , HN4 (squamous) ( 38 ) , HT-29 (intestinal) ( 1 , 178 , 254 , 334 , 378 ) , HT1080 (fibroblast) ( 43 ) , hTERT-HME1 (epithelial) ( 15 ) , HUVEC (endothelial) ( 28 ) , JAR (placental) ( 156 ) , JEKO-1 (B lymphocyte) ( 12 ) , Jurkat (T lymphocyte) ( 56 , 60 , 103 , 172 , 173 , 203 , 204 , 226 , 227 , 277 , 279 , 280 , 291 , 313 , 335 , 336 , 337 , 338 , 341 , 342 , 343 , 344 , 345 , 346 , 347 , 348 , 349 , 350 , 351 , 352 ) , K562 (erythroid) ( 13 , 14 , 16 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 164 , 165 , 166 , 167 , 282 , 283 , 284 , 285 , 286 , 287 , 288 , 289 , 301 , 302 , 332 , 333 , 368 ) , Karpas-422 (B lymphocyte) ( 39 ) , KBM-5 (myeloid) ( 14 ) , KMS-18 (B lymphocyte) ( 303 , 304 ) , liver ( 152 , 157 , 158 , 159 , 160 , 161 , 174 , 290 ) , LNCaP (prostate cell) ( 24 , 60 , 76 , 169 , 264 ) , LNCaP clone FGC (prostate cell) ( 26 ) , LOU-NH91 (squamous) ( 45 ) , lung ( 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 290 ) , lymphoblast ( 68 , 163 ) , lymphoblastoid ( 289 ) , MCF-10A (breast cell) ( 15 ) , MCF-7 (breast cell) ( 7 , 36 , 150 , 156 , 225 , 265 , 383 ) , MCF10A1 (epithelial) ( 36 ) , MDA-MB-231 (breast cell) ( 21 , 43 , 225 ) , MDA-MB-436 (breast cell) ( 43 ) , MDA-MB-468 (breast cell) ( 21 ) , MEF (fibroblast) ( 9 , 130 , 140 , 260 , 278 ) , MEL (erythroid) ( 35 , 147 ) , MG63 (bone cell) ( 263 ) , MKN-45 (gastric) ( 65 , 170 , 315 , 316 ) , MM (B lymphocyte) ( 257 , 258 , 259 ) , MM1.S (lymphoblast) ( 69 ) , MOLT-4 (T lymphocyte) ( 289 ) , monocyte-blood ( 6 ) , mononuclear-blood ( 182 ) , MV4-11 (macrophage) ( 176 , 250 , 295 , 296 , 297 , 324 , 339 , 354 , 355 , 356 ) , myometrial ( 61 ) , N87 (gastric) ( 11 ) , NB-4 (myeloid) ( 59 , 60 , 153 ) , NCI-H128 (pulmonary) ( 49 ) , NCI-H1299 (pulmonary) ( 52 ) , NCI-H1355 (pulmonary) ( 51 ) , NCI-H1417 (pulmonary) ( 49 ) , NCI-H1437 (pulmonary) ( 47 , 48 ) , NCI-H1650 (pulmonary) ( 53 ) , NCI-H1666 (pulmonary) ( 47 ) , NCI-H1703 (squamous) ( 45 , 67 ) , NCI-H1734 (pulmonary) ( 52 ) , NCI-H1781 (pulmonary) ( 46 ) , NCI-H1792 (pulmonary) ( 51 ) , NCI-H1944 (pulmonary) ( 52 ) , NCI-H1975 (pulmonary) ( 53 ) , NCI-H2073 (pulmonary) ( 45 , 48 ) , NCI-H209 (pulmonary) ( 48 , 49 ) , NCI-H2106 (pulmonary) ( 53 ) , NCI-H2228 (pulmonary) ( 46 , 58 , 205 , 206 , 207 , 208 ) , NCI-H23 (pulmonary) ( 51 , 388 ) , NCI-H2342 (pulmonary) ( 45 ) , NCI-H2405 (pulmonary) ( 47 ) , NCI-H3122 (pulmonary) ( 46 , 57 ) , NCI-H3255 (pulmonary) ( 66 , 369 , 370 , 384 , 385 ) , NCI-H358 (pulmonary) ( 52 ) , NCI-H441 (pulmonary) ( 51 ) , NCI-H446 (pulmonary) ( 50 ) , NCI-H460 (pulmonary) ( 52 , 265 ) , NCI-H520 (squamous) ( 386 , 387 ) , NCI-H524 (pulmonary) ( 49 ) , NCI-H526 (pulmonary) ( 50 ) , NCI-H661 (pulmonary) ( 46 ) , NCI-H69 (pulmonary) ( 50 ) , NCI-H716 (intestinal) ( 380 ) , NCI-H82 (pulmonary) ( 50 ) , NCI-H838 (pulmonary) ( 48 ) , NHF (fibroblast) ( 72 ) , OC-NYH (pulmonary) ( 381 ) , OCI-ly3 (B lymphocyte) ( 321 , 326 , 329 , 330 ) , OCI/AML2 (myeloid) ( 396 ) , OCI/AML3 (myeloid) ( 397 ) , osteoblast-calvarium ( 129 ) , OVCA429 (ovarian) ( 43 ) , PC3 (prostate cell) ( 26 , 169 ) , Pfeiffer (B lymphocyte) ( 12 ) , placenta ( 40 ) , prostate ( 76 , 181 , 264 ) , RC-K8 (B lymphocyte) ( 318 , 319 , 320 , 325 , 327 , 328 ) , Reh (B lymphocyte) ( 127 , 292 , 305 , 306 , 307 ) , RKO (intestinal) ( 1 , 406 ) , SEM (B lymphocyte) ( 293 , 308 , 309 , 310 ) , SF-295 (glial) ( 265 ) , SF9 ( 60 ) , SGC7901 (gastric) ( 170 ) , SiHa (squamous) ( 32 ) , SKOV-3 (ovarian) ( 29 , 43 ) , spleen ( 317 ) , squamous ( 154 ) , SR (T lymphocyte) ( 60 ) , stomach ( 241 ) , SU-DHL-2 (B lymphocyte) ( 12 ) , SU-DHL-4 (B lymphocyte) ( 39 ) , SW48 (intestinal) ( 379 , 406 ) , SW480 (intestinal) ( 149 , 364 , 365 , 390 ) , SW620 (intestinal) ( 265 , 353 , 366 , 367 , 391 ) , T lymphocyte ( 71 ) , T lymphocyte-blood ( 103 ) , T lymphocyte-lymph node ( 201 ) , T lymphocyte-spleen ( 201 ) , T-ALL (T lymphocyte) ( 5 ) , thymocyte ( 63 ) , thymus ( 109 ) , TOV-21G (epithelial) ( 43 ) , TOV112D (ovarian) ( 43 ) , U-937 (myeloid) ( 128 , 153 , 210 ) , U2OS (bone cell) ( 180 ) , UOK-101 (renal) ( 270 , 271 )

Upstream Regulation
Regulatory protein:
AMPKA1 (human) ( 251 ) , CtIP (human) ( 11 ) , E2F1 (human) ( 72 ) , EHMT2 (human) ( 18 ) , FXR1 (human) ( 403 ) , H2AX (human) ( 144 ) , HAT1 (human) ( 15 ) , HDAC1 (human) ( 63 ) , HDAC2 (human) ( 63 ) , HMGN1 (human) ( 267 ) , MBD3 (human) ( 75 ) , Myb (human) ( 103 ) , Myc (human) ( 266 ) , MYST1 (human) ( 225 ) , NFkB-p65 (human) ( 2 ) , OGT (human) ( 77 ) , p53 (human) ( 3 , 405 ) , PC4 (human) ( 146 ) , PHF8 (human) ( 59 ) , PKN1 (human) ( 264 ) , PRMT1 (mouse) ( 147 ) , PRMT5 (human) ( 12 ) , RGC32 (human) ( 149 ) , SIRT6 (human) ( 9 ) , SMARCA2 (human) ( 144 ) , SMARCA4 (human) ( 144 ) , SUV39H1 (human) ( 140 ) , TCF7L2 (human) ( 6 ) , TRRAP (human) ( 162 ) , ZNF263 (human) ( 10 )
Treatments:
5-aza-CdR ( 170 ) , A-485 ( 26 ) , A23187 ( 398 ) , acadesine ( 251 ) , acetate ( 17 ) , acidosis ( 32 ) , AzaC ( 156 ) , bacterial infection ( 33 ) , BIX01294 ( 38 ) , BMS-3031 ( 17 ) , BMX ( 1 ) , bortezomib ( 69 ) , butyrate ( 71 , 150 ) , C646 ( 24 ) , C8 MCT Oil Supplement ( 4 ) , camptothecin ( 180 ) , CDCA ( 403 ) , ciglitazone ( 150 ) , compound 1 ( 37 ) , compound 2 ( 37 ) , compound_3 ( 37 ) , compound_8 ( 37 ) , DCA ( 17 ) , DDATHF ( 405 ) , depsipeptide ( 265 ) , dexamethasone ( 40 , 155 ) , DRB ( 180 ) , DTBR ( 180 ) , estradiol ( 383 ) , etoposide ( 405 ) , exercise ( 168 ) , glucose ( 15 ) , glucose_starvation ( 177 ) , gold nanoparticles ( 21 ) , H2O2 ( 68 , 180 ) , hemorrhage ( 290 ) , hypertonic_buffer ( 290 ) , ionizing_radiation ( 144 , 180 ) , KU-55933 ( 180 ) , lactated Ringer’s ( 290 ) , LBH-589 ( 16 , 69 ) , liothyronine ( 179 , 183 ) , LPS ( 17 ) , LY294002 ( 150 ) , medium change ( 180 ) , metribolone ( 264 ) , MMS ( 180 ) , MS275 ( 176 , 263 ) , NaB ( 178 ) , nicotinamide ( 9 , 24 ) , PD98059 ( 150 , 155 ) , phleomycin ( 180 ) , phorbol_ester ( 210 , 383 ) , plumbagin ( 174 ) , PXD101 ( 150 ) , retinoic_acid ( 153 ) , Ro31-8220 ( 264 ) , selisistat ( 32 ) , siRNA ( 10 , 15 , 32 , 40 , 72 , 80 , 144 , 264 ) , SP600125 ( 75 ) , TGF-beta ( 34 ) , TMZ ( 1 ) , TNF ( 2 , 38 , 61 ) , trichostatin_A ( 24 , 33 , 40 , 80 , 130 , 140 , 150 , 156 , 170 , 183 , 254 , 278 , 290 , 406 ) , troglitazone ( 150 ) , UK5099 ( 17 ) , UNC0638 ( 35 ) , UV ( 72 , 180 ) , valproic acid ( 34 , 290 ) , vorinostat ( 29 , 176 , 290 ) , wortmannin ( 180 ) , zymosan ( 17 )

Downstream Regulation
Effects of modification on H3:
acetylation ( 2 ) , enzymatic activity, induced ( 199 ) , intracellular localization ( 3 , 13 , 18 ) , methylation ( 393 ) , molecular association, regulation ( 2 , 8 , 18 , 40 , 70 , 78 , 171 , 184 , 209 , 249 , 263 , 281 ) , protein degradation ( 7 )
Effects of modification on biological processes:
apoptosis, induced ( 5 , 16 ) , carcinogenesis, induced ( 29 , 63 , 149 , 170 ) , carcinogenesis, inhibited ( 37 ) , cell cycle regulation ( 5 , 18 , 63 , 149 , 180 ) , cell differentiation, induced ( 74 , 147 , 155 , 178 ) , cell growth, induced ( 18 , 29 , 80 ) , cell growth, inhibited ( 155 ) , chromatin organization, altered ( 63 , 73 , 74 , 78 , 103 , 145 , 146 , 147 , 149 , 153 , 175 , 178 , 209 , 250 , 263 , 265 ) , DNA repair, induced ( 5 , 72 ) , neural plasticity ( 80 ) , transcription, altered ( 3 , 55 , 63 , 145 , 254 , 263 , 267 , 290 , 406 ) , transcription, induced ( 2 , 5 , 6 , 18 , 28 , 29 , 32 , 40 , 59 , 68 , 69 , 73 , 74 , 75 , 80 , 103 , 146 , 147 , 148 , 149 , 153 , 155 , 163 , 175 , 178 , 180 , 182 , 200 , 201 , 250 , 265 , 266 , 289 , 331 , 403 ) , transcription, inhibited ( 2 , 70 , 170 , 183 )
Induce interaction with:
14-3-3 zeta (human) ( 249 ) , BRD7 (human) ( 281 ) , CHD-1 (human) ( 184 ) , CHD-4 (human) ( 171 ) , CRH (human) ( 40 ) , DNA ( 209 , 263 ) , MLL (human) ( 8 ) , PCAF (human) ( 18 ) , RARA (human) ( 2 ) , RARB (human) ( 2 ) , TIF1B (human) ( 184 ) , TIF1G (human) ( 70 ) , WSTF (human) ( 184 )
Inhibit interaction with:
DNA ( 78 )

Disease / Diagnostics Relevance
Relevant diseases:
gastric cancer ( 241 ) , prostate cancer ( 145 , 169 ) , diabetes mellitus ( 55 ) , type 2 diabetes ( 6 ) , FRDA ( 256 ) , Marfan syndrome ( 73 ) , SLE ( 3 )

References 

1

Ko HJ, et al. (2022) BMX, a specific HDAC8 inhibitor, with TMZ for advanced CRC therapy: a novel synergic effect to elicit p53-, β-catenin- and MGMT-dependent apoptotic cell death. Cell Commun Signal 20, 200
36575468   Curated Info

2

Song H, et al. (2022) NFκB induces epigenetic repression of GPRC5A in lung epithelial cells to promote neoplasia. JCI Insight
36413416   Curated Info

3

Zhang Q, et al. (2022) Deficiency of p53 Causes the Inadequate Expression of miR-1246 in B Cells of Systemic Lupus Erythematosus. J Immunol 209, 1492-1498
36165173   Curated Info

4

Neudorf H, Jackson G, Little JP (2022) Examining the Effect of Consuming C Medium-Chain Triglyceride Oil for 14 Days on Markers of NLRP3 Activation in Healthy Humans. J Nutr Metab 2022, 7672759
35433045   Curated Info

5

Lee M, et al. (2022) Adipocyte-mediated epigenomic instability in human T-ALL cells is cytotoxic and phenocopied by epigenetic-modifying drugs. Front Cell Dev Biol 10, 909557
36060800   Curated Info

6

Bompada P, et al. (2021) Epigenome-Wide Histone Acetylation Changes in Peripheral Blood Mononuclear Cells in Patients with Type 2 Diabetes and Atherosclerotic Disease. Biomedicines 9
34944721   Curated Info

7

Yang PB, et al. (2020) Blocking PPARγ interaction facilitates Nur77 interdiction of fatty acid uptake and suppresses breast cancer progression. Proc Natl Acad Sci U S A 117, 27412-27422
33087562   Curated Info

8

Ge M, et al. (2020) Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors. Oncogene 39, 5888-5901
32733069   Curated Info

9

Peng L, et al. (2020) Deacetylase-independent function of SIRT6 couples GATA4 transcription factor and epigenetic activation against cardiomyocyte apoptosis. Nucleic Acids Res 48, 4992-5005
32239217   Curated Info

10

Yu Z, et al. (2020) The EGFR-ZNF263 signaling axis silences SIX3 in glioblastoma epigenetically. Oncogene 39, 3163-3178
32051553   Curated Info

11

Yu Y, et al. (2020) RBBP8/CtIP suppresses P21 expression by interacting with CtBP and BRCA1 in gastric cancer. Oncogene 39, 1273-1289
31636387   Curated Info

12

Karkhanis V, et al. (2020) Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma. J Biol Chem 295, 1165-1180
31822509   Curated Info

13

Lin HH, et al. (2020) Overexpression of FAM46A, a Non-canonical Poly(A) Polymerase, Promotes Hemin-Induced Hemoglobinization in K562 Cells. Front Cell Dev Biol 8, 414
32528962   Curated Info

14

Jung JH, et al. (2019) Farnesiferol C Induces Apoptosis in Chronic Myelogenous Leukemia Cells as an Imatinib Sensitizer via Caspase Activation and HDAC (Histone Deacetylase) Inactivation. Int J Mol Sci 20
31698777   Curated Info

15

Gruber JJ, et al. (2019) HAT1 Coordinates Histone Production and Acetylation via H4 Promoter Binding. Mol Cell 75, 711-724.e5
31278053   Curated Info

16

Chen SH, et al. (2019) HDAC1,2 Knock-Out and HDACi Induced Cell Apoptosis in Imatinib-Resistant K562 Cells. Int J Mol Sci 20
31071955   Curated Info

17

Márquez S, et al. (2019) Tricarboxylic Acid Cycle Activity and Remodeling of Glycerophosphocholine Lipids Support Cytokine Induction in Response to Fungal Patterns. Cell Rep 27, 525-536.e4
30970255   Curated Info

18

Srinivasan S, Shankar SR, Wang Y, Taneja R (2019) SUMOylation of G9a regulates its function as an activator of myoblast proliferation. Cell Death Dis 10, 250
30867409   Curated Info

19

Deng R, et al. (2018) HDAC is indispensable for IFN-¿¿-induced B7-H1 expression in gastric cancer. Clin Epigenetics
30537988   Curated Info

20

Guo H, et al. (2018) Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Oncogene
30361685   Curated Info

21

Surapaneni SK, Bashir S, Tikoo K (2018) Gold nanoparticles-induced cytotoxicity in triple negative breast cancer involves different epigenetic alterations depending upon the surface charge. Sci Rep
30115982   Curated Info

22

Li X, et al. (2018) Heritable, Allele-Specific Chromosomal Looping between Tandem Promoters Specifies Promoter Usage of SHC1. Mol Cell Biol
29440311   Curated Info

23

Wu Y, et al. (2018) Regulatory Roles of Histone Deacetylases 1 and 2 in Pb-induced Neurotoxicity. Toxicol Sci
29301062   Curated Info

24

Lee JH, et al. (2017) Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer Development. ACS Chem Biol 12, 2804-2814
28949514   Curated Info

25

Zhu Q, et al. (2017) Human CRL4DDB2 ubiquitin ligase preferentially regulates post-repair chromatin restoration of H3K56Ac through recruitment of histone chaperon CAF-1. Oncotarget
29262658   Curated Info

26

Lasko LM, et al. (2017) Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature 550, 128-132
28953875   Curated Info

27

Hideshima T, et al. (2017) HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget 8
29113288   Curated Info

28

Zhao Y, et al. (2017) Induction of reprogramming of human amniotic epithelial cells into iPS cells by overexpression of Yap, Oct4, and Sox2 through the activation of the Hippo-Yap pathway. Exp Ther Med 14, 199-206
28672915   Curated Info

29

Gatla HR, et al. (2017) Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells. J Biol Chem 292, 5043-5054
28167529   Curated Info

30

Ferreira RC, et al. (2016) Histone Deacetylase 1 Is Essential for Rod Photoreceptor Differentiation by Regulating Acetylation at Histone H3 Lysine 9 and Histone H4 Lysine 12 in the Mouse Retina. J Biol Chem
28028172   Curated Info

31

Wang L, et al. (2016) Activin/Smad2-induced Histone H3 Lys-27 Trimethylation (H3K27me3) Reduction Is Crucial to Initiate Mesendoderm Differentiation of Human Embryonic Stem Cells. J Biol Chem
27965357   Curated Info

32

Corbet C, et al. (2016) Acidosis Drives the Reprogramming of Fatty Acid Metabolism in Cancer Cells through Changes in Mitochondrial and Histone Acetylation. Cell Metab 24, 311-23
27508876   Curated Info

33

Fischer N, et al. (2016) Histone deacetylase inhibition enhances antimicrobial peptide but not inflammatory cytokine expression upon bacterial challenge. Proc Natl Acad Sci U S A 113, E2993-3001
27162363   Curated Info

34

Noguchi S, et al. (2015) Regulation of Gene Expression by Sodium Valproate in Epithelial-to-Mesenchymal Transition. Lung 193, 691-700
26286207   Curated Info

35

Renneville A, et al. (2015) EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. Blood 126, 1930-9
26320100   Curated Info

36

Sidoli S, et al. (2015) Sequential Window Acquisition of all Theoretical Mass Spectra (SWATH) Analysis for Characterization and Quantification of Histone Post-translational Modifications. Mol Cell Proteomics 14, 2420-8
25636311   Curated Info

37

Sociali G, et al. (2015) Quinazolinedione SIRT6 inhibitors sensitize cancer cells to chemotherapeutics. Eur J Med Chem 102, 530-9
26310895   Curated Info

38

Liu S, et al. (2015) G9a is essential for EMT-mediated metastasis and maintenance of cancer stem cell-like characters in head and neck squamous cell carcinoma. Oncotarget 6, 6887-901
25749385   Curated Info

39

Johnson DP, et al. (2015) HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma. Oncotarget 6, 4863-87
25605023   Curated Info

40

Di Stefano V, et al. (2015) RelB/p52-mediated NF-κB signaling alters histone acetylation to increase the abundance of corticotropin-releasing hormone in human placenta. Sci Signal 8, ra85
26307012   Curated Info

41

Wu Q, et al. (2015) Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line. Sci Rep 5, 9520
25825284   Curated Info

42

Xing Z, et al. (2014) lncRNA Directs Cooperative Epigenetic Regulation Downstream of Chemokine Signals. Cell 159, 1110-25
25416949   Curated Info

43

Ullal AV, et al. (2014) Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates. Sci Transl Med 6, 219ra9
24431113   Curated Info

44

Jiang Y, et al. (2014) PKM2 regulates chromosome segregation and mitosis progression of tumor cells. Mol Cell 53, 75-87
24316223   Curated Info

45

Rikova K (2013) CST Curation Set: 20218; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

46

Rikova K (2013) CST Curation Set: 20219; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

47

Rikova K (2013) CST Curation Set: 20220; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

48

Rikova K (2013) CST Curation Set: 20221; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

49

Rikova K (2013) CST Curation Set: 20213; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

50

Rikova K (2013) CST Curation Set: 20214; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

51

Rikova K (2013) CST Curation Set: 20215; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

52

Rikova K (2013) CST Curation Set: 20216; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

53

Rikova K (2013) CST Curation Set: 20217; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

54

Weinert BT, et al. (2013) Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep 4, 842-51
23954790   Curated Info

55

Zhong Q, Kowluru RA (2013) Regulation of matrix metalloproteinase-9 by epigenetic modifications and the development of diabetic retinopathy. Diabetes 62, 2559-68
23423566   Curated Info

56

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

57

Rikova K (2013) CST Curation Set: 18855; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

58

Rikova K (2013) CST Curation Set: 18854; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

59

Arteaga MF, et al. (2013) The histone demethylase PHF8 governs retinoic acid response in acute promyelocytic leukemia. Cancer Cell 23, 376-89
23518351   Curated Info

60

Wu SY, et al. (2013) Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol Cell 49, 843-57
23317504   Curated Info

61

Webster SJ, et al. (2013) Regulation of GTP-binding Protein (Gαs) Expression in Human Myometrial Cells: A ROLE FOR TUMOR NECROSIS FACTOR IN MODULATING Gαs PROMOTER ACETYLATION BY TRANSCRIPTIONAL COMPLEXES. J Biol Chem 288, 6704-16
23297421   Curated Info

62

Nair SS, Li DQ, Kumar R (2013) A Core Chromatin Remodeling Factor Instructs Global Chromatin Signaling through Multivalent Reading of Nucleosome Codes. Mol Cell 49, 704-18
23352453   Curated Info

63

Dovey OM, et al. (2013) Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability in mice. Blood 121, 1335-44
23287868   Curated Info

64

Kuo YM, Andrews AJ (2013) Quantitating the specificity and selectivity of gcn5-mediated acetylation of histone h3. PLoS One 8, e54896
23437046   Curated Info

65

Rikova K (2012) CST Curation Set: 16030; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

66

Rikova K (2012) CST Curation Set: 16031; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

67

Rikova K (2012) CST Curation Set: 16032; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

68

Du W, et al. (2012) The FA pathway counteracts oxidative stress through selective protection of antioxidant defense gene promoters. Blood 119, 4142-51
22408259   Curated Info

69

Mannava S, et al. (2012) KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood 119, 1450-8
22144178   Curated Info

70

Agricola E, et al. (2011) Recruitment of TIF1γ to chromatin via its PHD finger-bromodomain activates its ubiquitin ligase and transcriptional repressor activities. Mol Cell 43, 85-96
21726812   Curated Info

71

Ishiguro K, et al. (2011) Cutting edge: tubulin α functions as an adaptor in NFAT-importin β interaction. J Immunol 186, 2710-3
21278340   Curated Info

72

Guo R, Chen J, Mitchell DL, Johnson DG (2011) GCN5 and E2F1 stimulate nucleotide excision repair by promoting H3K9 acetylation at sites of damage. Nucleic Acids Res 39, 1390-7
20972224   Curated Info

73

Gomez D, et al. (2011) Epigenetic control of vascular smooth muscle cells in Marfan and non-Marfan thoracic aortic aneurysms. Cardiovasc Res 89, 446-56
20829218   Curated Info

74

Kim H, Jang MJ, Kang MJ, Han YM (2011) Epigenetic signatures and temporal expression of lineage-specific genes in hESCs during differentiation to hepatocytes in vitro. Hum Mol Genet 20, 401-12
21059703   Curated Info

75

Aguilera C, et al. (2011) c-Jun N-terminal phosphorylation antagonises recruitment of the Mbd3/NuRD repressor complex. Nature 469, 231-5
21196933   Curated Info

76

Huang PH, et al. (2011) Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. Mol Pharmacol 79, 197-206
20959362   Curated Info

77

Sakabe K, Hart GW (2010) O-GlcNAc transferase regulates mitotic chromatin dynamics. J Biol Chem 285, 34460-8
20805223   Curated Info

78

Szerlong HJ, Prenni JE, Nyborg JK, Hansen JC (2010) Activator-dependent p300 acetylation of chromatin in vitro: enhancement of transcription by disruption of repressive nucleosome-nucleosome interactions. J Biol Chem 285, 31954-64
20720004   Curated Info

79

Plazas-Mayorca MD, et al. (2010) Quantitative proteomics reveals direct and indirect alterations in the histone code following methyltransferase knockdown. Mol Biosyst 6, 1719-29
20577673   Curated Info

80

Gaub P, et al. (2010) HDAC inhibition promotes neuronal outgrowth and counteracts growth cone collapse through CBP/p300 and P/CAF-dependent p53 acetylation. Cell Death Differ 17, 1392-408
20094059   Curated Info

81

Li Y (2010) CST Curation Set: 10374; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

82

Li Y (2010) CST Curation Set: 10376; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

83

Li Y (2010) CST Curation Set: 10388; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

84

Li Y (2010) CST Curation Set: 10380; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

85

Li Y (2010) CST Curation Set: 10383; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

86

Li Y (2010) CST Curation Set: 10377; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

87

Li Y (2010) CST Curation Set: 10375; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

88

Li Y (2010) CST Curation Set: 10399; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

89

Li Y (2010) CST Curation Set: 10392; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

90

Li Y (2010) CST Curation Set: 10379; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

91

Li Y (2010) CST Curation Set: 10381; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

92

Li Y (2010) CST Curation Set: 10396; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

93

Li Y (2010) CST Curation Set: 10395; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

94

Li Y (2010) CST Curation Set: 10387; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

95

Li Y (2010) CST Curation Set: 10397; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

96

Li Y (2010) CST Curation Set: 10386; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

97

Li Y (2010) CST Curation Set: 10378; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

98

Li Y (2010) CST Curation Set: 10382; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

99

Li Y (2010) CST Curation Set: 10385; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

100

Li Y (2010) CST Curation Set: 10384; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

101

Li Y (2010) CST Curation Set: 10394; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

102

Li Y (2010) CST Curation Set: 10373; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

103

Nakata Y, et al. (2010) c-Myb, Menin, GATA-3, and MLL form a dynamic transcription complex that plays a pivotal role in human T helper type 2 cell development. Blood 116, 1280-90
20484083   Curated Info

104

Li Y (2010) CST Curation Set: 10350; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

105

Li Y (2010) CST Curation Set: 10329; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

106

Li Y (2010) CST Curation Set: 10338; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

107

Li Y (2010) CST Curation Set: 10341; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

108

Li Y (2010) CST Curation Set: 10326; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

109

Li Y (2010) CST Curation Set: 10344; Year: 2010; Biosample/Treatment: tissue, thymus/untreated; Disease: thymic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

110

Li Y (2010) CST Curation Set: 10327; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

111

Li Y (2010) CST Curation Set: 10339; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

112

Li Y (2010) CST Curation Set: 10334; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

113

Li Y (2010) CST Curation Set: 10322; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

114

Li Y (2010) CST Curation Set: 10348; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

115

Li Y (2010) CST Curation Set: 10337; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

116

Li Y (2010) CST Curation Set: 10323; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

117

Li Y (2010) CST Curation Set: 10349; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

118

Li Y (2010) CST Curation Set: 10340; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

119

Li Y (2010) CST Curation Set: 10332; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

120

Li Y (2010) CST Curation Set: 10320; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

121

Li Y (2010) CST Curation Set: 10330; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

122

Li Y (2010) CST Curation Set: 10333; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

123

Li Y (2010) CST Curation Set: 10360; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

124

Li Y (2010) CST Curation Set: 10354; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

125

Li Y (2010) CST Curation Set: 10356; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

126

Li Y (2010) CST Curation Set: 10353; Year: 2010; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

127

Tucker M (2010) CST Curation Set: 10224; Year: 2010; Biosample/Treatment: cell line, Reh/SAHA 6h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

128

Darwanto A, et al. (2010) A modified "cross-talk" between histone H2B Lys-120 ubiquitination and H3 Lys-79 methylation. J Biol Chem 285, 21868-76
20442396   Curated Info

129

Gordon JA, et al. (2010) Pbx1 represses osteoblastogenesis by blocking Hoxa10-mediated recruitment of chromatin remodeling factors. Mol Cell Biol 30, 3531-41
20439491   Curated Info

130

Jiang X, Xu Y, Price BD (2010) Acetylation of H2AX on lysine 36 plays a key role in the DNA double-strand break repair pathway. FEBS Lett 584, 2926-30
20488183   Curated Info

131

Moritz A (2010) CST Curation Set: 9922; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

132

Moritz A (2010) CST Curation Set: 9919; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

133

Moritz A (2010) CST Curation Set: 9921; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

134

Moritz A (2010) CST Curation Set: 9818; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

135

Moritz A (2010) CST Curation Set: 9817; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

136

Moritz A (2010) CST Curation Set: 9820; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

137

Moritz A (2010) CST Curation Set: 9823; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

138

Moritz A (2010) CST Curation Set: 9819; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

139

Moritz A (2010) CST Curation Set: 9822; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

140

Horáková AH, et al. (2010) SUV39h-independent association of HP1 beta with fibrillarin-positive nucleolar regions. Chromosoma 119, 227-41
20033197   Curated Info

141

Moritz A (2010) CST Curation Set: 9796; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

142

Moritz A (2010) CST Curation Set: 9797; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

143

Moritz A (2010) CST Curation Set: 9794; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

144

Lee HS, et al. (2010) A cooperative activation loop among SWI/SNF, gamma-H2AX and H3 acetylation for DNA double-strand break repair. EMBO J 29, 1434-45
20224553   Curated Info

145

Zhou LX, et al. (2010) Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy. Asian J Androl 12, 171-9
19935671   Curated Info

146

Das C, Gadad SS, Kundu TK (2010) Human positive coactivator 4 controls heterochromatinization and silencing of neural gene expression by interacting with REST/NRSF and CoREST. J Mol Biol 397, 1-12
20080105   Curated Info

147

Li X, et al. (2010) H4R3 methylation facilitates beta-globin transcription by regulating histone acetyltransferase binding and H3 acetylation. Blood 115, 2028-37
20068219   Curated Info

148

Paakinaho V, Makkonen H, Jääskeläinen T, Palvimo JJ (2010) Glucocorticoid receptor activates poised FKBP51 locus through long-distance interactions. Mol Endocrinol 24, 511-25
20093418   Curated Info

149

Vlaicu SI, et al. (2010) Epigenetic modifications induced by RGC-32 in colon cancer. Exp Mol Pathol 88, 67-76
19883641   Curated Info

150

Davies GF, et al. (2010) Troglitazone inhibits histone deacetylase activity in breast cancer cells. Cancer Lett 288, 236-50
19699029   Curated Info

151

Possemato A (2010) CST Curation Set: 8997; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

152

Zhao S, et al. (2010) Regulation of cellular metabolism by protein lysine acetylation. Science 327, 1000-4
20167786   Curated Info

153

Martens JH, et al. (2010) PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell 17, 173-185
20159609   Curated Info

154

I H, et al. (2010) Association of global levels of histone modifications with recurrence-free survival in stage IIB and III esophageal squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 19, 566-73
20142251   Curated Info

155

Inamochi Y, et al. (2010) Histone H3 methylation at lysine 4 on the SLC2A5 gene in intestinal Caco-2 cells is involved in SLC2A5 expression. Biochem Biophys Res Commun 392, 16-21
20043883   Curated Info

156

Dufau ML, Liao M, Zhang Y (2010) Participation of signaling pathways in the derepression of luteinizing hormone receptor transcription. Mol Cell Endocrinol 314, 221-7
19464346   Curated Info

157

Tucker M (2010) CST Curation Set: 8956; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

158

Tucker M (2010) CST Curation Set: 8955; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

159

Tucker M (2010) CST Curation Set: 8953; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

160

Tucker M (2010) CST Curation Set: 8952; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

161

Tucker M (2010) CST Curation Set: 8951; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

162

Wurdak H, et al. (2010) An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. Cell Stem Cell 6, 37-47
20085741   Curated Info

163

Calero-Nieto FJ, Bert AG, Cockerill PN (2010) Transcription-dependent silencing of inducible convergent transgenes in transgenic mice. Epigenetics Chromatin 3, 3
20180972   Curated Info

164

Moritz A (2009) CST Curation Set: 8728; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

165

Moritz A (2009) CST Curation Set: 8730; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

166

Moritz A (2009) CST Curation Set: 8729; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

167

Moritz A (2009) CST Curation Set: 8727; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

168

McGee SL, Fairlie E, Garnham AP, Hargreaves M (2009) Exercise-induced histone modifications in human skeletal muscle. J Physiol 587, 5951-8
19884317   Curated Info

169

Cang S, et al. (2009) Deficient histone acetylation and excessive deacetylase activity as epigenomic marks of prostate cancer cells. Int J Oncol 35, 1417-22
19885564   Curated Info

170

Meng CF, Zhu XJ, Peng G, Dai DQ (2009) Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells. Oncol Rep 22, 1221-7
19787243   Curated Info

171

Musselman CA, et al. (2009) Binding of the CHD4 PHD2 finger to histone H3 is modulated by covalent modifications. Biochem J 423, 179-87
19624289   Curated Info

172

Moritz A (2009) CST Curation Set: 7940; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

173

Moritz A (2009) CST Curation Set: 7941; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

174

Ravindra KC, et al. (2009) Inhibition of lysine acetyltransferase KAT3B/p300 activity by a naturally occurring hydroxynaphthoquinone, plumbagin. J Biol Chem 284, 24453-64
19570987   Curated Info

175

Hinshelwood RA, et al. (2009) Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning. Hum Mol Genet 18, 3098-109
19477956   Curated Info

176

Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40
19608861   Curated Info

177

Zhou Y, et al. (2009) Reversible acetylation of the chromatin remodelling complex NoRC is required for non-coding RNA-dependent silencing. Nat Cell Biol 11, 1010-6
19578370   Curated Info

178

Strasák L, et al. (2009) H3K9 acetylation and radial chromatin positioning. J Cell Physiol 220, 91-101
19248079   Curated Info

179

Umezawa R, et al. (2009) Aberrant histone modifications at the thyrotropin-releasing hormone gene in resistance to thyroid hormone: analysis of F455S mutant thyroid hormone receptor. Endocrinology 150, 3425-32
19299458   Curated Info

180

Tjeertes JV, Miller KM, Jackson SP (2009) Screen for DNA-damage-responsive histone modifications identifies H3K9Ac and H3K56Ac in human cells. EMBO J 28, 1878-89
19407812   Curated Info

181

Paradowska A, et al. (2009) Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia. Int J Oncol 35, 87-96
19513555   Curated Info

182

Araki Y, et al. (2009) Genome-wide analysis of histone methylation reveals chromatin state-based regulation of gene transcription and function of memory CD8+ T cells. Immunity 30, 912-25
19523850   Curated Info

183

Wang D, et al. (2009) Negative regulation of TSHalpha target gene by thyroid hormone involves histone acetylation and corepressor complex dissociation. Mol Endocrinol 23, 600-9
19196836   Curated Info

184

Chan DW, et al. (2009) Unbiased proteomic screen for binding proteins to modified lysines on histone H3. Proteomics 9, 2343-54
19337993   Curated Info

185

Li Y (2009) CST Curation Set: 6526; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

186

Li Y (2009) CST Curation Set: 6528; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

187

Li Y (2009) CST Curation Set: 6527; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

188

Li Y (2009) CST Curation Set: 6522; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

189

Li Y (2009) CST Curation Set: 6525; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

190

Li Y (2009) CST Curation Set: 6521; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

191

Li Y (2009) CST Curation Set: 6524; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

192

Li Y (2009) CST Curation Set: 6520; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

193

Li Y (2009) CST Curation Set: 6514; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

194

Li Y (2009) CST Curation Set: 6513; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

195

Li Y (2009) CST Curation Set: 6511; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

196

Li Y (2009) CST Curation Set: 6509; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

197

Li Y (2009) CST Curation Set: 6510; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

198

Li Y (2009) CST Curation Set: 6512; Year: 2009; Biosample/Treatment: tissue, colon/0.1% serum; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

199

Southall SM, et al. (2009) Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks. Mol Cell 33, 181-91
19187761   Curated Info

200

Akan P, Sahlén M, Deloukas P (2009) A histone map of human chromosome 20q13.12. PLoS One 4, e4479
19229332   Curated Info

201

Hiragami-Hamada K, et al. (2009) The molecular basis for stability of heterochromatin-mediated silencing in mammals. Epigenetics Chromatin 2, 14
19889207   Curated Info

202

Dryhurst D, et al. (2009) Characterization of the histone H2A.Z-1 and H2A.Z-2 isoforms in vertebrates. BMC Biol 7, 86
20003410   Curated Info

203

Possemato A (2008) CST Curation Set: 5684; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

204

Possemato A (2008) CST Curation Set: 5685; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

205

Rikova K (2008) CST Curation Set: 5646; Year: 2008; Biosample/Treatment: cell line, NCI-H2228/DMSO; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

206

Rikova K (2008) CST Curation Set: 5649; Year: 2008; Biosample/Treatment: cell line, NCI-H2228/inhibitor; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

207

Rikova K (2008) CST Curation Set: 5647; Year: 2008; Biosample/Treatment: cell line, NCI-H2228/inhibitor; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

208

Rikova K (2008) CST Curation Set: 5648; Year: 2008; Biosample/Treatment: cell line, NCI-H2228/inhibitor; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

209

Kang TJ, Yuzawa S, Suga H (2008) Expression of histone H3 tails with combinatorial lysine modifications under the reprogrammed genetic code for the investigation on epigenetic markers. Chem Biol 15, 1166-74
19022177   Curated Info

210

Pless O, et al. (2008) G9a-mediated lysine methylation alters the function of CCAAT/enhancer-binding protein-beta. J Biol Chem 283, 26357-63
18647749   Curated Info

211

Possemato A (2008) CST Curation Set: 5212; Year: 2008; Biosample/Treatment: cell line, HCT116/TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

212

Possemato A (2008) CST Curation Set: 5213; Year: 2008; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

213

Li Y (2008) CST Curation Set: 4814; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

214

Li Y (2008) CST Curation Set: 4815; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

215

Li Y (2008) CST Curation Set: 4816; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

216

Li Y (2008) CST Curation Set: 4817; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

217

Li Y (2008) CST Curation Set: 4810; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

218

Li Y (2008) CST Curation Set: 4811; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

219

Li Y (2008) CST Curation Set: 4812; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

220

Li Y (2008) CST Curation Set: 4813; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

221

Li Y (2008) CST Curation Set: 4806; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

222

Li Y (2008) CST Curation Set: 4807; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

223

Li Y (2008) CST Curation Set: 4808; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

224

Li Y (2008) CST Curation Set: 4809; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

225

Kapoor-Vazirani P, Kagey JD, Powell DR, Vertino PM (2008) Role of hMOF-dependent histone H4 lysine 16 acetylation in the maintenance of TMS1/ASC gene activity. Cancer Res 68, 6810-21
18701507   Curated Info

226

Possemato A (2008) CST Curation Set: 4822; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

227

Possemato A (2008) CST Curation Set: 4823; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

228

Li Y (2008) CST Curation Set: 4802; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

229

Li Y (2008) CST Curation Set: 4804; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

230

Li Y (2008) CST Curation Set: 4805; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

231

Li Y (2008) CST Curation Set: 4800; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

232

Li Y (2008) CST Curation Set: 4801; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

233

Li Y (2008) CST Curation Set: 4798; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

234

Li Y (2008) CST Curation Set: 4799; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

235

Li Y (2008) CST Curation Set: 4757; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

236

Li Y (2008) CST Curation Set: 4758; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

237

Li Y (2008) CST Curation Set: 4767; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

238

Li Y (2008) CST Curation Set: 4768; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

239

Li Y (2008) CST Curation Set: 4755; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

240

Li Y (2008) CST Curation Set: 4797; Year: 2008; Biosample/Treatment: cell line, A549/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

241

Park YS, et al. (2008) The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 15, 1968-76
18470569   Curated Info

242

Li Y (2008) CST Curation Set: 4796; Year: 2008; Biosample/Treatment: cell line, A549/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

243

Li Y (2008) CST Curation Set: 4642; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

244

Li Y (2008) CST Curation Set: 4643; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

245

Li Y (2008) CST Curation Set: 4644; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

246

Li Y (2008) CST Curation Set: 4645; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

247

Li Y (2008) CST Curation Set: 4646; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

248

Li Y (2008) CST Curation Set: 4647; Year: 2008; Biosample/Treatment: tissue, colon/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

249

Winter S, Fischle W, Seiser C (2008) Modulation of 14-3-3 interaction with phosphorylated histone H3 by combinatorial modification patterns. Cell Cycle 7, 1336-42
18418070   Curated Info

250

Wiencke JK, Zheng S, Morrison Z, Yeh RF (2008) Differentially expressed genes are marked by histone 3 lysine 9 trimethylation in human cancer cells. Oncogene 27, 2412-21
17968314   Curated Info

251

McGee SL, et al. (2008) AMP-activated protein kinase regulates GLUT4 transcription by phosphorylating histone deacetylase 5. Diabetes 57, 860-7
18184930   Curated Info

252

Li Y (2008) CST Curation Set: 4227; Year: 2008; Biosample/Treatment: cell line, HCT116/SAHA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

253

Li Y (2008) CST Curation Set: 4228; Year: 2008; Biosample/Treatment: cell line, HCT116/LCMS75; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

254

Ellis DJ, Lawman ZK, Bonham K (2008) Histone acetylation is not an accurate predictor of gene expression following treatment with histone deacetylase inhibitors. Biochem Biophys Res Commun 367, 656-62
18179771   Curated Info

255

Warnock LJ, Adamson R, Lynch CJ, Milner J (2008) Crosstalk between site-specific modifications on p53 and histone H3. Oncogene 27, 1639-44
17891183   Curated Info

256

Al-Mahdawi S, et al. (2008) The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum Mol Genet 17, 735-46
18045775   Curated Info

257

Li Y (2008) CST Curation Set: 3783; Year: 2008; Biosample/Treatment: cell line, MM/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

258

Li Y (2008) CST Curation Set: 3784; Year: 2008; Biosample/Treatment: cell line, MM/SAHA; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

259

Li Y (2008) CST Curation Set: 3785; Year: 2008; Biosample/Treatment: cell line, MM/maz1584; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

260

Shimada M, et al. (2008) Chk1 is a histone H3 threonine 11 kinase that regulates DNA damage-induced transcriptional repression. Cell 132, 221-32
18243098   Curated Info

261

Li Y (2008) CST Curation Set: 3754; Year: 2008; Biosample/Treatment: cell line, HCT116/SAHA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

262

Li Y (2008) CST Curation Set: 3755; Year: 2008; Biosample/Treatment: cell line, HCT116/LCMS75; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

263

Aoyama T, et al. (2008) Cell-specific epigenetic regulation of ChM-I gene expression: crosstalk between DNA methylation and histone acetylation. Biochem Biophys Res Commun 365, 124-30
17980151   Curated Info

264

Metzger E, et al. (2008) Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. Nat Cell Biol 10, 53-60
18066052   Curated Info

265

To KK, et al. (2008) Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res 6, 151-64
18234970   Curated Info

266

Martinato F, Cesaroni M, Amati B, Guccione E (2008) Analysis of Myc-induced histone modifications on target chromatin. PLoS One 3, e3650
18985155   Curated Info

267

Zhu N, Hansen U (2007) HMGN1 modulates estrogen-mediated transcriptional activation through interactions with specific DNA-binding transcription factors. Mol Cell Biol 27, 8859-73
17938209   Curated Info

268

Rikova K (2007) CST Curation Set: 3511; Year: 2007; Biosample/Treatment: cell line, 786-0 vector/untreated; Disease: kidney cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

269

Rikova K (2007) CST Curation Set: 3513; Year: 2007; Biosample/Treatment: cell line, 786-0 VHL-30/untreated; Disease: kidney cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

270

Rikova K (2007) CST Curation Set: 3515; Year: 2007; Biosample/Treatment: cell line, UOK-101/untreated; Disease: kidney cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

271

Rikova K (2007) CST Curation Set: 3517; Year: 2007; Biosample/Treatment: cell line, UOK-101/untreated; Disease: kidney cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

272

Li Y (2007) CST Curation Set: 3506; Year: 2007; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

273

Li Y (2007) CST Curation Set: 3507; Year: 2007; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

274

Li Y (2007) CST Curation Set: 3508; Year: 2007; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

275

Li Y (2007) CST Curation Set: 3509; Year: 2007; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

276

Li Y (2007) CST Curation Set: 3510; Year: 2007; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

277

Stokes M (2007) CST Curation Set: 3465; Year: 2007; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

278

Dai B, Rasmussen TP (2007) Global epiproteomic signatures distinguish embryonic stem cells from differentiated cells. Stem Cells 25, 2567-74
17641388   Curated Info

279

Possemato A (2007) CST Curation Set: 3231; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

280

Possemato A (2007) CST Curation Set: 3232; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

281

Sun H, et al. (2007) Solution structure of BRD7 bromodomain and its interaction with acetylated peptides from histone H3 and H4. Biochem Biophys Res Commun 358, 435-41
17498659   Curated Info

282

Possemato A (2007) CST Curation Set: 2992; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

283

Possemato A (2007) CST Curation Set: 2994; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

284

Possemato A (2007) CST Curation Set: 2995; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

285

Possemato A (2007) CST Curation Set: 2996; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

286

Possemato A (2007) CST Curation Set: 2997; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

287

Possemato A (2007) CST Curation Set: 2998; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

288

Possemato A (2007) CST Curation Set: 2999; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

289

Koch CM, et al. (2007) The landscape of histone modifications across 1% of the human genome in five human cell lines. Genome Res 17, 691-707
17567990   Curated Info

290

Lin T, et al. (2007) Histone deacetylase as therapeutic target in a rodent model of hemorrhagic shock: effect of different resuscitation strategies on lung and liver. Surgery 141, 784-94
17560255   Curated Info

291

Possemato A (2007) CST Curation Set: 2865; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

292

Cherry J (2007) CST Curation Set: 2821; Year: 2007; Biosample/Treatment: cell line, Reh/DMSO; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

293

Cherry J (2007) CST Curation Set: 2826; Year: 2007; Biosample/Treatment: cell line, SEM/SAHA 6h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

294

Cherry J (2007) CST Curation Set: 2789; Year: 2007; Biosample/Treatment: cell line, Nomo-1/DMSO; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

295

Cherry J (2007) CST Curation Set: 2792; Year: 2007; Biosample/Treatment: cell line, MV4-11/DMSO; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

296

Cherry J (2007) CST Curation Set: 2793; Year: 2007; Biosample/Treatment: cell line, MV4-11/SAHA 3h; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

297

Cherry J (2007) CST Curation Set: 2794; Year: 2007; Biosample/Treatment: cell line, MV4-11/SAHA 6h; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

298

Cherry J (2007) CST Curation Set: 2726; Year: 2007; Biosample/Treatment: cell line, KMS-12-BM/DMSO; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

299

Cherry J (2007) CST Curation Set: 2730; Year: 2007; Biosample/Treatment: cell line, KMS-12-BM/SAHA 3h; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

300

Cherry J (2007) CST Curation Set: 2731; Year: 2007; Biosample/Treatment: cell line, KMS-12-BM/SAHA 6h; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

301

Possemato A (2007) CST Curation Set: 2735; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

302

Possemato A (2007) CST Curation Set: 2737; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

303

Cherry J (2007) CST Curation Set: 2727; Year: 2007; Biosample/Treatment: cell line, KMS-18/DMSO; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

304

Cherry J (2007) CST Curation Set: 2729; Year: 2007; Biosample/Treatment: cell line, KMS-18/SAHA 6h; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

305

Cherry J (2007) CST Curation Set: 2707; Year: 2007; Biosample/Treatment: cell line, Reh/DMSO; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

306

Cherry J (2007) CST Curation Set: 2708; Year: 2007; Biosample/Treatment: cell line, Reh/SAHA 3h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

307

Cherry J (2007) CST Curation Set: 2709; Year: 2007; Biosample/Treatment: cell line, Reh/SAHA 6h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

308

Cherry J (2007) CST Curation Set: 2710; Year: 2007; Biosample/Treatment: cell line, SEM/DMSO; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

309

Cherry J (2007) CST Curation Set: 2711; Year: 2007; Biosample/Treatment: cell line, SEM/SAHA 3h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

310

Cherry J (2007) CST Curation Set: 2712; Year: 2007; Biosample/Treatment: cell line, SEM/SAHA 6h; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

311

Li Y (2007) CST Curation Set: 2694; Year: 2007; Biosample/Treatment: cell line, HCT116/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

312

Li Y (2007) CST Curation Set: 2698; Year: 2007; Biosample/Treatment: cell line, HCT116/untreated &'||' nicotinamide; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

313

Farnsworth C (2007) CST Curation Set: 2671; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

314

comb b (2007) CST Curation Set: 2621; Year: 2007; Biosample/Treatment: cell line, HCC827/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

315

comb b (2007) CST Curation Set: 2623; Year: 2007; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

316

comb b (2007) CST Curation Set: 2624; Year: 2007; Biosample/Treatment: cell line, MKN-45/untreated &'||' TSA; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

317

Garcia BA, et al. (2007) Organismal differences in post-translational modifications in histones H3 and H4. J Biol Chem 282, 7641-55
17194708   Curated Info

318

Cherry J (2007) CST Curation Set: 2509; Year: 2007; Biosample/Treatment: cell line, RC-K8/DMSO; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

319

Cherry J (2007) CST Curation Set: 2511; Year: 2007; Biosample/Treatment: cell line, RC-K8/SAHA 3h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

320

Cherry J (2007) CST Curation Set: 2512; Year: 2007; Biosample/Treatment: cell line, RC-K8/SAHA 6h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

321

Cherry J (2007) CST Curation Set: 2514; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/SAHA 6h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

322

Cherry J (2007) CST Curation Set: 2472; Year: 2007; Biosample/Treatment: cell line, Nomo-1/DMSO; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

323

Cherry J (2007) CST Curation Set: 2473; Year: 2007; Biosample/Treatment: cell line, Nomo-1/SAHA 3h; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

324

Cherry J (2007) CST Curation Set: 2477; Year: 2007; Biosample/Treatment: cell line, MV4-11/SAHA 6h; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

325

Cherry J (2007) CST Curation Set: 2436; Year: 2007; Biosample/Treatment: cell line, RC-K8/DMSO; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

326

Cherry J (2007) CST Curation Set: 2437; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/DMSO; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

327

Cherry J (2007) CST Curation Set: 2438; Year: 2007; Biosample/Treatment: cell line, RC-K8/SAHA 3h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

328

Cherry J (2007) CST Curation Set: 2439; Year: 2007; Biosample/Treatment: cell line, RC-K8/SAHA 6h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

329

Cherry J (2007) CST Curation Set: 2440; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/SAHA 3h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

330

Cherry J (2007) CST Curation Set: 2441; Year: 2007; Biosample/Treatment: cell line, OCI-ly3/SAHA 6h; Disease: B cell lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

331

Appanah R, et al. (2007) An unmethylated 3' promoter-proximal region is required for efficient transcription initiation. PLoS Genet 3, e27
17305432   Curated Info

332

Possemato A (2007) CST Curation Set: 2412; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

333

Possemato A (2007) CST Curation Set: 2413; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

334

Li Y (2007) CST Curation Set: 2374; Year: 2007; Biosample/Treatment: cell line, HT-29/untreated &'||' nicotinamide; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

335

Possemato A (2007) CST Curation Set: 2336; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

336

Possemato A (2007) CST Curation Set: 2337; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

337

Possemato A (2007) CST Curation Set: 2343; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

338

Possemato A (2007) CST Curation Set: 2344; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

339

Cherry J (2007) CST Curation Set: 2312; Year: 2007; Biosample/Treatment: cell line, MV4-11/DMSO; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

340

Cherry J (2007) CST Curation Set: 2316; Year: 2007; Biosample/Treatment: cell line, Nomo-1/SAHA; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

341

Moritz A (2007) CST Curation Set: 2292; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

342

Moritz A (2007) CST Curation Set: 2293; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

343

Moritz A (2007) CST Curation Set: 2287; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

344

Moritz A (2007) CST Curation Set: 2288; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

345

Moritz A (2007) CST Curation Set: 2289; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

346

Moritz A (2007) CST Curation Set: 2290; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

347

Moritz A (2007) CST Curation Set: 2291; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

348

Possemato A (2006) CST Curation Set: 2192; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

349

Possemato A (2006) CST Curation Set: 2193; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

350

Possemato A (2006) CST Curation Set: 2194; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

351

Possemato A (2006) CST Curation Set: 2195; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

352

Possemato A (2006) CST Curation Set: 2187; Year: 2006; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

353

Li Y (2006) CST Curation Set: 2117; Year: 2006; Biosample/Treatment: cell line, SW620/untreated &'||' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

354

Cherry J (2006) CST Curation Set: 2029; Year: 2006; Biosample1/Treatment/Isotope: cell line, MV4-11/SAHA/L, Biosample2/Treatment/Isotope: cell line, MV4-11/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

355

Cherry J (2006) CST Curation Set: 2030; Year: 2006; Biosample1/Treatment/Isotope: cell line, MV4-11/SAHA/L, Biosample2/Treatment/Isotope: cell line, MV4-11/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

356

Cherry J (2006) CST Curation Set: 2032; Year: 2006; Biosample1/Treatment/Isotope: cell line, MV4-11/SAHA/L, Biosample2/Treatment/Isotope: cell line, MV4-11/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

357

Cherry J (2006) CST Curation Set: 2033; Year: 2006; Biosample1/Treatment/Isotope: cell line, Nomo-1/SAHA/L, Biosample2/Treatment/Isotope: cell line, Nomo-1/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

358

Cherry J (2006) CST Curation Set: 2034; Year: 2006; Biosample1/Treatment/Isotope: cell line, Nomo-1/SAHA/L, Biosample2/Treatment/Isotope: cell line, Nomo-1/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

359

Cherry J (2006) CST Curation Set: 2035; Year: 2006; Biosample1/Treatment/Isotope: cell line, Nomo-1/SAHA/L, Biosample2/Treatment/Isotope: cell line, Nomo-1/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

360

Cherry J (2006) CST Curation Set: 2036; Year: 2006; Biosample1/Treatment/Isotope: cell line, Nomo-1/SAHA/L, Biosample2/Treatment/Isotope: cell line, Nomo-1/DMSO/H; Disease: acute myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

361

Li Y (2006) CST Curation Set: 1998; Year: 2006; Biosample/Treatment: cell line, HCT116/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

362

Li Y (2006) CST Curation Set: 1999; Year: 2006; Biosample/Treatment: cell line, HCT116/serum starved &'||' EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

363

Li Y (2006) CST Curation Set: 2000; Year: 2006; Biosample/Treatment: cell line, HCT116/serum starved &'||' EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

364

Li Y (2006) CST Curation Set: 1971; Year: 2006; Biosample/Treatment: cell line, SW480/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

365

Li Y (2006) CST Curation Set: 1972; Year: 2006; Biosample/Treatment: cell line, SW480/untreated &'||' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

366

Li Y (2006) CST Curation Set: 1973; Year: 2006; Biosample/Treatment: cell line, SW620/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

367

Li Y (2006) CST Curation Set: 1974; Year: 2006; Biosample/Treatment: cell line, SW620/untreated &'||' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

368

Moritz A (2006) CST Curation Set: 1968; Year: 2006; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

369

Guo A (2006) CST Curation Set: 1852; Year: 2006; Biosample1/Treatment/Isotope: cell line, NCI-H3255/TSA 6h/L, Biosample2/Treatment/Isotope: cell line, NCI-H3255/none/H; Disease: non-small cell lung cancer; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

370

Guo A (2006) CST Curation Set: 1853; Year: 2006; Biosample1/Treatment/Isotope: cell line, NCI-H3255/TSA 24h/L, Biosample2/Treatment/Isotope: cell line, NCI-H3255/none/H; Disease: non-small cell lung cancer; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

371

Guo A (2006) CST Curation Set: 1854; Year: 2006; Biosample1/Treatment/Isotope: cell line, HCC78/TSA 6h/L, Biosample2/Treatment/Isotope: cell line, HCC78/none/H; Disease: non-small cell lung cancer; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

372

Guo A (2006) CST Curation Set: 1855; Year: 2006; Biosample1/Treatment/Isotope: cell line, HCC78/TSA 24h/L, Biosample2/Treatment/Isotope: cell line, HCC78/none/H; Disease: non-small cell lung cancer; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

373

Possemato A (2006) CST Curation Set: 1807; Year: 2006; Biosample/Treatment: cell line, HCC827/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

374

Possemato A (2006) CST Curation Set: 1808; Year: 2006; Biosample/Treatment: cell line, HCC78/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

375

Li Y (2006) CST Curation Set: 1810; Year: 2006; Biosample1/Treatment/Isotope: cell line, HCT116/serum starved &'||' EGF/L, Biosample2/Treatment/Isotope: cell line, HCT116/serum starved/serum starved/H; Disease: colorectal carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

376

Li Y (2006) CST Curation Set: 1659; Year: 2006; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

377

Kim SC, et al. (2006) Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 23, 607-18
16916647   Curated Info

378

Li Y (2006) CST Curation Set: 1632; Year: 2006; Biosample/Treatment: cell line, HT-29/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

379

Li Y (2006) CST Curation Set: 1564; Year: 2006; Biosample/Treatment: cell line, SW48/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

380

Li Y (2006) CST Curation Set: 1567; Year: 2006; Biosample/Treatment: cell line, NCI-H716/untreated &'||' TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

381

Beck HC, et al. (2006) Quantitative proteomic analysis of post-translational modifications of human histones. Mol Cell Proteomics 5, 1314-25
16627869   Curated Info

382

Miao F, et al. (2006) Coactivator-associated arginine methyltransferase-1 enhances nuclear factor-kappaB-mediated gene transcription through methylation of histone H3 at arginine 17. Mol Endocrinol 20, 1562-73
16497732   Curated Info

383

Espino PS, et al. (2006) Chromatin modification of the trefoil factor 1 gene in human breast cancer cells by the Ras/mitogen-activated protein kinase pathway. Cancer Res 66, 4610-6
16651411   Curated Info

384

Guo A (2006) CST Curation Set: 1208; Year: 2006; Biosample/Treatment: cell line, NCI-H3255/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

385

Guo A (2006) CST Curation Set: 1209; Year: 2006; Biosample/Treatment: cell line, NCI-H3255/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

386

Mitchell J (2006) CST Curation Set: 1210; Year: 2006; Biosample/Treatment: cell line, NCI-H520/serum starved; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

387

Mitchell J (2006) CST Curation Set: 1211; Year: 2006; Biosample/Treatment: cell line, NCI-H520/serum starved; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

388

Mitchell J (2006) CST Curation Set: 1213; Year: 2006; Biosample/Treatment: cell line, NCI-H23/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

389

Thomas CE, Kelleher NL, Mizzen CA (2006) Mass spectrometric characterization of human histone H3: a bird's eye view. J Proteome Res 5, 240-7
16457588   Curated Info

390

Li Y (2006) CST Curation Set: 1101; Year: 2006; Biosample/Treatment: cell line, SW480/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

391

Li Y (2006) CST Curation Set: 1103; Year: 2006; Biosample/Treatment: cell line, SW620/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

392

Hake SB, et al. (2006) Expression patterns and post-translational modifications associated with mammalian histone H3 variants. J Biol Chem 281, 559-68
16267050   Curated Info

393

Forneris F, et al. (2005) Human histone demethylase LSD1 reads the histone code. J Biol Chem 280, 41360-5
16223729   Curated Info

394

Mitchell J (2005) CST Curation Set: 1018; Year: 2005; Biosample/Treatment: cell line, HepG2/-; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

395

Mitchell J (2005) CST Curation Set: 1019; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA &'||' nicotinamide; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

396

Gu T (2005) CST Curation Set: 957; Year: 2005; Biosample/Treatment: cell line, OCI/AML2/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

397

Gu T (2005) CST Curation Set: 958; Year: 2005; Biosample/Treatment: cell line, OCI/AML3/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

398

Huang W, et al. (2005) Increases in intracellular calcium dephosphorylate histone H3 at serine 10 in human hepatoma cells: potential role of protein phosphatase 2A-protein kinase CbetaII complex. J Cell Physiol 205, 37-46
15880462   Curated Info

399

Mitchell J (2005) CST Curation Set: 867; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

400

Mitchell J (2005) CST Curation Set: 868; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

401

Mitchell J (2005) CST Curation Set: 869; Year: 2005; Biosample/Treatment: cell line, HepG2/TSA; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

402

Guo A (2005) CST Curation Set: 762; Year: 2005; Biosample/Treatment: cell line, HeLa/TSA; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441
Curated Info

403

Ananthanarayanan M, et al. (2004) Ligand-dependent activation of the farnesoid X-receptor directs arginine methylation of histone H3 by CARM1. J Biol Chem 279, 54348-57
15471871   Curated Info

404

Pal S, et al. (2004) Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol 24, 9630-45
15485929   Curated Info

405

Bronder JL, Moran RG (2003) A defect in the p53 response pathway induced by de novo purine synthesis inhibition. J Biol Chem 278, 48861-71
14517211   Curated Info

406

Kondo Y, Shen L, Issa JP (2003) Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol 23, 206-15
12482974   Curated Info

407

Edmondson DG, et al. (2002) Site-specific loss of acetylation upon phosphorylation of histone H3. J Biol Chem 277, 29496-502
12039950   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.